Research article - Peer-reviewed, 2018
A novel adjuvant G3 induces both Th1 and Th2 related immune responses in mice after immunization with a trivalent inactivated split-virion influenza vaccine
Hjertner, Bernt; Bengtsson, Theresa; Morein, Bror; Paulie, Staffan; Fossum, CarolineAbstract
A preferred adjuvant should promote both Th1 and Th2 responses. However, most adjuvants in common use are biased towards a Th2-driven response. Therefore, the ability of a novel saponin-based adjuvant G3 to inducing balanced Thl and Th2 responses in BALB/c mice immunized with a split trivalent seasonal influenza vaccine was evaluated in comparison to that of the adjuvant Al(OH) 3 . Clear differences in the IgG profiles induced by G3, Al(OH)(3) or non-adjuvanted vaccine were recorded. Both adjuvants enhanced high and similar levels of the Th2 associated IgG1 subtype compared to mice given vaccine alone. Only G3 enhanced the IgG2a subclass reflecting a Th1 response, whereas Al(OH)(3) even abrogated the IgG2a production. Accordingly, G3 enhanced the production of IL-2 and IFN-gamma and also of IL-2/IFN-gamma double secreting cells, emphasizing the strong Th1 driving effect of G3. Only Al(OH)(3) increased splenocyte production of IL-17. Taken together, the results indicate a strong propensity for G3 to induce both Th1 and Th2 driven immune responses. (C) 2018 The Authors. Published by Elsevier Ltd.Keywords
Adjuvant; Th1 /Th2; Cytokine production; InfluenzaPublished in
Vaccine2018, volume: 36, number: 23, pages: 3340-3344
Publisher: ELSEVIER SCI LTD
Authors' information
Swedish University of Agricultural Sciences, Department of Biomedical Science and Veterinary Public Health
Bengtsson, Theresa
Mabtech
Swedish University of Agricultural Sciences, Department of Biomedical Science and Veterinary Public Health
Paulie, Staffan
Mabtech
Swedish University of Agricultural Sciences, Department of Biomedical Science and Veterinary Public Health
Sustainable Development Goals
SDG3 Good health and well-being
UKÄ Subject classification
Immunology in the medical area
Publication Identifiers
DOI: https://doi.org/10.1016/j.vaccine.2018.04.054
URI (permanent link to this page)
https://res.slu.se/id/publ/95889